Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey

Gabriella Macchia, Aldo Sainato, Renato Talamini, Giovanni Boz, Almalina Bacigalupo, Luciana Caravatta, Michele Fiore, Maria Luisa Friso, Vincenzo Fusco, Marco Lupattelli, Giovanna Mantello, Gian Carlo Mattiucci, Najla Slim, Piera Sciacero, Lucia Turri, Vincenzo Valentini, Alessio Giuseppe Morganti, Domenico Genovesi

Research output: Contribution to journalArticlepeer-review

Abstract

No information is currently available regarding pancreatic cancer (PC) pattern of care in Italy. In the present study, a nationwide survey using a questionnaire was performed to enquire the local standards for PC diagnosis and radiotherapy treatment. Fifty-seven percent of 140 Italian centres completed questionnaire. The main causes of no radiotherapy indication were poor general condition (45%) and lack of guidelines (25%). Physicians (38%) employed neoadjuvant therapy in locally advanced PC patients, while in other centres (62%) adjuvant chemoradiation was administered. Adjuvant gemcitabine-based chemotherapy was selected as the treatment of choice by 59% of centres. Patients were treated mostly with doses of 50-54.9 Gy on the tumour (or bed) plus lymph nodes. A 3D-CRT technique was used in 81.2% of centres, while IMRT and IGRT were available in 61.2 and 48.7% of cases, respectively. Extensive variation exists with regard to patterns of care for PC in Italy. Nevertheless, cooperative studies emerging from this survey appeared beneficial.

Original languageEnglish
Pages (from-to)382-390
Number of pages9
JournalOncology Reports
Volume34
Issue number1
DOIs
Publication statusPublished - Jul 1 2015

Keywords

  • Italy
  • Pancreatic cancer
  • Pattern of care
  • Radiotherapy
  • Survey

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey'. Together they form a unique fingerprint.

Cite this